NILOTINIB SHOWS SUSTAINED BENEFIT COMPARED WITH IMATINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND 4-YEAR FOLLOW-UP (F/U) A. Hochhaus,G. Saglio,R. Larson,G. Rosti,Ian Flinn,Y. Goh, P. Llacer,K. Porkka, Y. Kanda, L. Stenke,C. Kemp, X. Fan, H. Menssen,H. Kantarjian,T. HughesHAEMATOLOGICA（2013）引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
